Abstract
The detection of circulating tumor cells (CTCs) has recently received great attention. To evaluate if miR-421 could be used as a specific marker for CTCs, the level of miR-421 in mononuclear cells (MNCs) from peripheral blood were determined by reverse transcription-polymerase chain reaction. Transfection of miR-421 inhibitor significantly suppressed tumor growth in vivo. The level of miR-421 in MNCs from gastric cancer was significantly higher than in those from healthy controls. The area under the receiver operating characteristic curve was 0.773 ± 0.0736. In conclusion, miR-421 may be used as a biomarker for monitoring CTCs in patients with gastric cancer.
Publication types
-
Multicenter Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Animals
-
Biomarkers, Tumor / blood
-
Carcinoma / blood
-
Carcinoma / diagnosis*
-
Carcinoma / pathology
-
Case-Control Studies
-
Cell Line, Tumor
-
China
-
Female
-
Humans
-
Leukocytes, Mononuclear / metabolism*
-
Leukocytes, Mononuclear / pathology
-
Male
-
Mice
-
Mice, Nude
-
MicroRNAs / blood
-
Middle Aged
-
Neoplastic Cells, Circulating / metabolism*
-
Neoplastic Cells, Circulating / pathology
-
RNA, Neoplasm / antagonists & inhibitors
-
RNA, Neoplasm / genetics
-
ROC Curve
-
Ribonucleotides / administration & dosage
-
Ribonucleotides / therapeutic use
-
Stomach Neoplasms / blood
-
Stomach Neoplasms / diagnosis*
-
Stomach Neoplasms / pathology
-
Xenograft Model Antitumor Assays
Substances
-
Biomarkers, Tumor
-
MIRN421 microRNA, human
-
MicroRNAs
-
RNA, Neoplasm
-
Ribonucleotides